Assessment of knowledge and awareness about clinical trials of patients participating in cancer trials
More details
Hide details
Department of Immunobiology, Poznan University of Medical Sciences
Department of Chemotherapy, The Greater Poland Cancer Center, Poznan, Poland
Mikołaj Bartoszkiewicz   

Department of Immunobiology, Poznan University of Medical Sciences
Submission date: 2020-10-26
Final revision date: 2020-12-03
Acceptance date: 2020-12-03
Online publication date: 2021-03-01
Clinical research in the field of oncology is necessary to check the safety and effectiveness of potential treatment methods and translate innovative knowledge into measurable benefits for patients as well as to introduce innovative therapies for cancer treatment. In 2019, 18.1 million new cancer cases were diagnosed worldwide.

The purpose of this study is to assess patients knowledge and awareness of the clinical trials they participate in, as well as the quality of treatment in the clinical trial compared to standard treatment.

Material and methods:
The authors anonymous questionnaire was used to assess the state of knowledge of patients. Seventy patients in clinical trials participated in the study, 87% of whom were women, and 13% were men. The patient’s knowledge was compared with the actual state of research in the chemotherapy department, and general questions about clinical trials were asked.

Results and discussion:
Most often, patients gained knowledge about clinical trials from the attending physician (37%). As many as 79% of study participants were satisfied with the informed consent procedure. The factor that most determined the participation in the clinical trial (36%) was access to innovative therapy not available in the national healthcare system. Every fourth participant in the study was unable to determine the phase of participation in clinical trials.

Based on anonymous survey results, patients who participate in clinical trials know the clinical trials essential parts. The vast majority are satisfied with the informed consent process, the availability of innovative therapies, and a clinical trial phase.

None declared.
None declared.
Brodniewicz T. [Clinical trials]. In: Brodniewicz T, ed. [Clinical Trials]. 1st Ed. Warsaw: CeDeWu; 2015:79–80 [in Polish].
Newman LA, Roff NK, Weinberg AD. Cancer clinical trials accrual: Missed opportunities to address disparities and missed opportunities to improve outcomes for all. Ann Surg Oncol. 2008;15(7):1818–1819.
Cierniak-Piotrowska M, Marciniak G, Stańczak J. Statistics of deaths and mortality from cardiovascular diseases. In: Strzelecki Z, Szymborski J, eds. Morbidity and Mortality from Cardiovascular Diseases and Demographic Situation of Poland, Warsaw: Central Statistical Office, 2015. Accessed: 30.07.2019.
Bray F, Ferlay J, Soerjomataram I, Siegel, RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Central Statistical Office. Population. Condition and Structure as Well as Natural Movement in the Territorial Profile in 2018. As of December 31. Accessed: 30.07.2019 [in Polish].
U.S. National Library of Medicine. Clinical Trials Database. Accessed: 30.07.2020.
PwC. [Clinical trials in Poland]. Warszawa: PwC; 2015. Accessed: 01.08.2020.
Viergever RF, Li K. Trends in global clinical trial registration: an analysis of numbers of registered clinical trials in different parts of the world from 2004 to 2013. BMJ Open. 2015;5(9):e008932.
Schroen AT, Petroni GR, Wang H, et al. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res. 2012;18(1):256–262.
Health System Tracker. Health Spending. https://www.healthsystemtracke.... Accessed: 03.08.2020.
Leiter A, Diefenbach MA, Doucette J, Oh WK, Galsky MD. Clinical trial awareness: Changes over time and sociodemographic disparities. Clin Trials. 2015;12(3):215–223.
Du W, Mood D, Gadgeel S, Simon MS. An educational video to increase clinical trials enrollment among lung cancer patients. J Throatic Oncology. 2008;3(1):23–29.
Alexa-Stratulat T, Neagu M, Neagu AI, Alexa ID, Ioan BG. Consent for participating in clinical Ttrials – Is it really informed? Dev World Bioeth. 2018;18(3):299–306.
Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel J. Patients’ decision-making process regarding participation in phase I oncology research. J Clin Oncol. 2006;24(27):4479–4484.
Anderson A, Borfitz D, Getz K. Global public attitudes about clinical research and patient experiences with clinical trials. JAMA Netw Open. 2018;1(6):e182969.
Tam NT, Huy NT, Thoa le TB, et al. Participants’ understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis. Bull World Health Organ. 2015;93(3):186–198H.
DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: Is biotech different? Manage Decis Econ. 2007;28(4–5):469–479.
Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G. Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Patient Educ Couns. 2006;63(1–2):104–109.
Frąckowiak L, Frąckowiak H. Organization and functioning of Regional Commission for Evaluation of Medical Events after a year of operation. Pol Ann Med. 2013;20(1):82–87.
Carey M, Boyes AW, Smits R, Bryant J, Waller A, Olver I. Access to clinical trials among oncology patients: Results of a cross sectional survey. BMC Cancer. 2017;17:653.